Parthenon Therapeutics has announced the publication of its research in the Journal for ImmunoTherapy of Cancer, which shows how PRTH-101 can inhibit collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells and reverse immune exclusion. The study was conducted with George Washington University and The University of Texas Health Center at Houston. Parthenon recently initiated a Phase 1 first-in-human clinical trial for PRTH-101 in patients with advanced solid tumors.
Precision oncology company Parthenon Therapeutics has published research that demonstrates its lead candidate, PRTH-101, inhibits DDR1-expressing cancer cells to collagen substrates and autophosphorylation induced by collagen. This allows T-cells to enter tumours and attack them. The study was conducted with George Washington University and The University of Texas Health Center at Houston. Parthenon recently started a Phase 1 first-in-human clinical trial for PRTH-101 in patients with advanced solid tumours.